精确搜索
我的草稿
我的购物车
精确搜索
产品分类
产品变更说明-C610034
尊敬的客户：
因产品产品信息优化，经过公司管理层审批同意，我们将对如下产品执行信息变更。计划执行时间为 2026/09/23 ，期间可能会出现实际交货产品变更前后两种情况共存的现象，生工生物深感歉意并希望得到您的谅解！我们承诺，本次变更不会对产品质量产生负面影响，敬请继续放心订购与使用。
| 产品编号 | 产品名称 | 变更类型 | 变更前 | 变更后 |
|---|---|---|---|---|
| C610034 | 重组人VEGF165 | 分子量 | Approximately 38.6 kDa, a disulfide-linked homodimeric protein consisting of two 166 amino acid polypeptide chains with Met at N-terminus. | Recombinant Human VEGF 165 Protein, a disulfide-linked non-glycosylated homodimer, each subunit containing 165 amino acid residues, has a predicted molecular mass of approximately 38.4 kDa |
| 属性-概述 | Vascular Endothelial Growth Factor is a sub-family of growth factors produced by cells, which stimulates vasculogenesis and angiogenesis. VEGFs normal function is to create new blood vessels during embryonic development, new blood vessels after injury, muscle following exercise, and new vessels (collateral circulation) to bypass blocked vessels. Humans express alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (a.a.) in length. VEGF production can be induced in cells that are not receiving enough oxygen. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. Recombinant human VEGF165 contains 165 amino acids residues and it is a disulfide-linked homodimer. In addition, it shares 88 % a.a. with corresponding regions of mouse and rat, 96 % with porcine, 95 % with canine, and 93 % with feline, equine and bovine VEGF, respectively. | Human Vascular Endothelial Growth Factor 165 (VEGF 165) is a non-glycosylated monomer expressed in E. coli, consisting of 165 amino acid residues with a predicted molecular mass of ~19.2 kDa. As a key pro-angiogenic factor, it plays essential roles in vascular development, angiogenesis, and vascular permeability. It binds to VEGFR receptors to promote endothelial cell proliferation and migration, with abnormal expression linked to cancer and ischemic disorders, serving as a vital target for related research. | ||
| 属性-Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. | Always centrifuge tubes before opening. Do not mix by vortex or pipetting. Reconstitute in sterile distilled water to a concentration of 0.1-1.0 mg/mL. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. | ||
| 属性-Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. | Lyophilized from a 0.22 μm filtered solution of in PBS and Tween-20. | ||
| 属性-Endotoxin | Less than 1 EU/μg of rHuVEGF165 as determined by LAL method. | Less than 0.1 EU/μg of rHuVEGF165 as determined by LAL test. | ||
| 属性-Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human umbilical vein endothelial cells(HUVEC) is between 1.0-8.0 ng/ml. | Determined by its ability to stimulate the proliferation of human umbilical vein endothelial cells (HUVEC). The expected ED50 for this effect is 1.0-8.0 ng/ml. | ||
| 属性-Purity | > 95 % by SDS-PAGE and HPLC analyses. | > 98% by SDS-PAGE gel and HPLC analyses. | ||
| 属性-Amino acid sequence | MAPMAEGGGQ NHHEVVKFMD VYQRSYCHPI ETLVDIFQEY PDEIEYIFKP SCVPLMRCGG CCNDEGLECV PTEESNITMQ IMRIKPHQGQ HIGEMSFLQH NKCECRPKKD RARQENPCGP CSERRKHLFV QDPQTCKCSC KNTDSRCKAR QLELNERTCR CDKPRR | Ala27-Arg191, Accession # P15692-4 |
生工生物工程（上海）股份有限公司
2026年9月23日 星期三